Jupiter is actively exploring additional strategic partnerships to expand JOTROL’s application across other neuroinflammatory and metabolic disorders, including Alzheimer’s disease and longevity ...

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based ...

Revolutionary nasal spray offers hope by potentially delaying Alzheimer's progression through cutting-edge neurological ...

Anavex’s newest patent will be expected to remain in force at least until July 2039, not including any patent term extensions. It will expand and supplement the current ANAVEX®2-73 (blarcamesine) ...

Turmeric (Curcuma longa), a vibrant yellow spice, a rhizomatous herbaceous plant from the ginger family (Zingiberaceae), has ...

Wildfire smoke, long recognized as a health threat to the lungs and heart, may also pose significant risks to brain health, ...

Advanced AI genetics models reveal key genetic markers and potential drug repurposing for Parkinson's disease, accelerating ...

Parkinson's disease research has also advanced, particularly in understanding the role of neuroinflammation in its progression. Studies have shown that inflammation and immune dysfunction are ...

The agreement will allow Enigma to use its PET imaging tracer PMI04 to visualize microglia activity in neurodegenerative ...

Jan. 15, 2025 — Regular aerobic exercise could significantly reduce disease markers associated ... Study Identifies Potential New Drug for Parkinson's-Related Cognitive Decline, Dementia Nov ...

Usnoflast (ZYIL1) is a novel, oral small molecule NLRP3 inhibitor. Usnoflast has been studied in several pre-clinical models of neuroinflammation, Parkinson’s disease, Inflammatory Bowel Disease (IBD) ...